Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa

NCT00638365 is registered in ClinicalTrials.gov with Humanigen, Inc. as lead sponsor.

NCT NCT00638365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00638365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa
Lead sponsor
Humanigen, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2008
Completion date
April 30, 2009
Enrollment
27 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis